Ivonescimab Mechanism of Action

Designed to optimize the balance of anti-tumor activity and safety4,5


Simultaneous interaction of PD-1 & VEGF blockades have the potential to drive synergistic anti-tumor activity1,4,5

Higher Binding Affinity
Presence of VEGF increases PD-1 binding strength by >18X6
Presence of PD-1 increases VEGF binding strength by >4X6

Increased Binding T Cells
VEGF dimer leads to potential interconnection or daisy chaining of multiple ivonescimab molecules, which may lead to increased binding of T cells6,7

Based on in-vitro studies

Without Ivonescimab

With Ivonescimab Cooperative Binding



For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.


  1. Manegold et al., (2016); JTO 12:2.194-207.;
  2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.;
  3. Tamura et al., (2020) Med Oncol 37:2, 10.1007.
  4. Zhao Y. et al., (August 2023) eClinicalMedicine vol 62: 102106.
  5. Zhou C. et al., Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 9040.
  6. Zhong T et al., (2022) Journal for ImmunoTherapy of Cancer 10(2) 521.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).